R&D
In this section you will find R&D market research reports and publications. These provide information on the latest products, news, market growth forecasts, data and business opportunities of value to your organization.
-
Biologicals in Oncology Drug Pipeline Update 2012
€2,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 669 companies plus partners who are today developing 1071 biological drugs in 2294 developmental projects in cancer across 408 different targets. In addition, there are 17 suspended drugs and another 676 drugs where development has been ceased. Learn More -
Analytical Tool - Leukemia
€3,100.00Published by BioSeeker Group on Feb 21st, 2012A unique tool for analyzing the complex competitive pressure within the different fields of leukemia therapeutics. Learn More -
IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 135 companies plus partners who are today developing 159 IL-3 pathway targeting drugs in 510 developmental projects in cancer across 118 different targets. In addition, there are 2 suspended drugs and another 71 drugs where development has been ceased. Learn More -
Nucleic Acid Therapies in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 204 companies plus partners who are today developing 229 nucleic acid therapy drugs in 520 developmental projects in cancer across 173 different targets. In addition, there are 7 suspended drugs and another 177 drugs where development has been ceased. Learn More -
Analytical Tool - Angiogenesis in Oncology
€3,100.00Published by BioSeeker Group on Feb 21st, 2012The ultimate tool for serious players who would like to understand the current competitive field in cancer drug development among anti-angiogenic and vascular targeting agents. Learn More -
IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2012
€999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 72 companies plus partners who are today developing 57 IL-1 pathway targeting drugs in 210 developmental projects in cancer across 63 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More -
FSH Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 157 companies plus partners who are today developing 178 FSH pathway targeting drugs in 610 developmental projects in cancer across 108 different targets. In addition, there are 2 suspended drugs and another 101 drugs where development has been ceased. Learn More -
Analytical Tool - Breast Cancer
€3,100.00Published by BioSeeker Group on Feb 21st, 2012The ultimate tool for serious players who would like to understand the current competitive field in breast cancer drug development. Learn More -
B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 166 companies plus partners who are today developing 209 B cell receptor pathway targeting drugs in 690 developmental projects in cancer across 142 different targets. In addition, there are 3 suspended drugs and another 87 drugs where development has been ceased. Learn More -
RANKL Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 164 companies plus partners who are today developing 192 RANKL pathway targeting drugs in 643 developmental projects in cancer across 104 different targets. In addition, there is 1 suspended drug and another 104 drugs where development has been ceased. Learn More -
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 286 companies plus partners who are today developing 352 Androgen Receptor drugs in 1074 developmental projects in cancer across 153 different targets. In addition, there are 3 suspended drugs and another 187 drugs where development has been ceased. Learn More -
TSH Signaling Pathway in Oncology Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 135 companies plus partners who are today developing 182 TSH pathway targeting drugs in 551 developmental projects in cancer across 121 different targets. In addition, there are 2 suspended drugs and another 81 drugs where development has been ceased. Learn More -
Lung Cancer Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 333 companies plus partners who are today developing 426 lung cancer drugs in 507 developmental projects in cancer across 243 different targets. In addition, there are 9 suspended drugs and another 189 drugs where development has been ceased. Learn More -
Notch Signaling Pathway in Oncology Drug Pipeline Update 2012
€999.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 149 companies plus partners who are today developing 152 Notch pathway targeting drugs in 481 developmental projects in cancer across 116 different targets. In addition, there are 2 suspended drugs and another 101 drugs where development has been ceased. Learn More -
Colorectal Cancer Drug Pipeline Update 2012
€1,499.00Published by BioSeeker Group on Feb 21st, 2012BioSeeker Group have identified 289 companies plus partners who are today developing 374 drugs targeting colorectal cancer in development. across 213 different targets. In addition, there are 5 suspended drugs and another 157 drugs where development has been ceased. Learn More